DNLI

$DNLI chatter on StockTwits

• 
  David Shapiro@B2iDigital3d

  eXoZymes (Nasdaq: $EXOZ) secures $2 million NIH grant, expanding its proprietary pharmaceutical biosolutions pipeline into non-intoxicating cannabinoids. Federal research funding extends eXoZymes’ cell-free platform further into drug discovery. eXoZymes Inc. (Nasdaq: EXOZ) has received a Notice of Award from the National Institutes of Health for a roughly $2 million Phase IIB SBIR grant to produce rare cannabinoids and engineer cannabinoid analogs for pharmaceutical evaluation. The award adds a second biosolution to the pipeline alongside NCT, expands the company’s portfolio of proprietary pharmaceutical assets, and lifts total non-dilutive funding awarded to eXoZymes and its predecessor programs to approximately $19.7 million. The two-year program begins July 1, 2026. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Michael Heltzen, CEO of eXoZymes, commented: “This is a key milestone that demonstrates our repeatable development engine of future licensing and partnering opportunities - a key feature in creating additional proprietary molecules without diluting shareholders.” From the announcement: • The grant supports work to build cannabinoid cyclase expression systems, widen the analog range, and run preclinical receptor-binding evaluation of the cannabinoid library • It arrives as the US minor cannabinoids market is forecast to grow from $11.5 billion in 2023 to $33.3 billion by 2030 See the full release: https://exozymes.com/blog/grant-cannabinoid-analogs eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  David Shapiro@B2iDigital5d

  eXoZymes (Nasdaq: $EXOZ ) Chief Commercial Officer Damien Perriman will present at Webull’s Biotech Sector webinar on June 25, alongside Envoy Medical and IN8bio. Damien Perriman, Chief Commercial Officer of eXoZymes Inc. (Nasdaq: EXOZ), will present at Webull’s Biotech Sector webinar on June 25 at 2:00 p.m. Eastern, part of the Webull Corporate Connect series that spotlights publicly traded biotech companies for investors. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 eXoZymes is a synthetic biology company that takes enzymes out of the living cell and runs them on their own to manufacture hard-to-make molecules for nutraceutical and pharmaceutical markets. The session gives investors a chance to hear directly from the company’s commercial leadership. • The webinar takes place June 25 at 2:00 p.m. Eastern, 11:00 a.m. Pacific, and registration is free with a Webull account • Perriman presents alongside Brent Lucas, Chief Executive Officer of Envoy Medical, and Will Ho, Chief Executive Officer and co-founder of IN8bio • Perriman leads commercial strategy at eXoZymes, whose cell-free platform uses AI-engineered enzymes to convert low-cost feedstocks into high-value compounds Register for the webinar: https://exozymes.com/blog/webulls-biotech-webinar-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJun 19

  eXoZymes says its platform can also produce cannabinoids, terpenes, and flavonoids. A May 2026 investor presentation from eXoZymes (Nasdaq: $EXOZ ) put the spotlight on the wider range of compounds its platform can make. Chairman Chris Marlett said cannabinoids are next in line, with terpenes and flavonoids behind them, and that the company is building its patents around the methods used to make these compounds. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Marlett traced the cannabinoid work back to the company’s earliest days: “So cannabinoids are next. Actually, ironically, it was the first thing we started to make. We started to make cannabinoids. We got grants to make it and we demonstrated that we could get yields.” The presentation also covered: • A platform the company says also extends to terpenes and flavonoids • A strategy to patent the methods used to make natural compounds, plus composition patents on engineered analogs and enzymes • A partnership model spanning contract manufacturers, supplement makers, and pharmaceutical companies • Recognition in scientific and news publications and grant funding the company cites as validation Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology. The company is building a pipeline of natural compounds and engineered analogs across nutraceutical and pharmaceutical applications. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  Horacio@MerlintraderJun 19

  $RCKT Rocket Pharmaceuticals & Denali Therapeutics (Nasdaq: $RCKT / $DNLI): Priority Review Vouchers, Non-Dilutive Cash and Runway https://www.merlintrader.com/rocket-denali-priority-review-voucher-cash/

  View on StockTwits ↗
• 
  clueless@buyslowsellfastJun 17

  Sold $DNLI 23.00. Still hold core 2021 position. Bought a trading lot 26 mar 2025. Will buy back at least part of it on a dip.

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJun 12

  eXoZymes names NCT, a compound tied to fat metabolism, as its lead molecule. NCT, a naturally occurring compound tied to how the body stores and burns fat, is the lead molecule for eXoZymes Inc. (NASDAQ: EXOZ). In a May 2026 investor presentation, Chairman Chris Marlett described how the company is pursuing it for markets such as obesity, type 2 diabetes, and fatty liver on both a nutraceutical and a pharmaceutical track. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 On what NCT does in the body, Marlett said: “...we see NCT as sort of a master metabolic switch that activates this pathway that really ramps up mitochondrial metabolization of fats and energy in your body and really could address the root of how the body stores and burns stored fat.” Marlett also noted: • Early data the company says points to measurable metabolic effects tied to NCT • A planned over the counter nutraceutical path, with market entry targeted following GRAS work • A parallel pharmaceutical path built around more potent NCT analogs • Interest from pharmaceutical companies exploring complements to GLP-1 therapies, per the company Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company applying AI engineered enzymes to produce natural molecules at scale. Its lead molecule, NCT, is being pursued on both a nutraceutical and a pharmaceutical track. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJun 9

  eXoZymes (Nasdaq: $EXOZ ) announced the pricing of a public offering expected to generate approximately $5.3 million in gross proceeds, with funding intended to support development of its NCT program, continued R&D, and general corporate initiatives. For investors following eXoZymes, the announcement is significant because it provides additional capital to advance the company's AI-enabled exozyme platform and its efforts to scale production of high-value molecules for nutraceutical, pharmaceutical, and specialty chemical markets. eXoZymes is focused on using engineered enzymes operating outside living cells to manufacture complex molecules at commercial scale, an approach the company believes can overcome limitations associated with traditional biomanufacturing methods. Read the full announcement: https://exozymes.com/blog/fundraise-pricing-2026 eXoZymes is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1. Disclosure: This post is for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation to purchase EXOZ or any other security. David Shapiro, CEO of B2i Digital, personally purchased shares of unrestricted EXOZ stock in the open market as part of B2i Digital's practice of investing alongside its Featured Companies. Investors should conduct their own due diligence and consult qualified financial and professional advisors before making any investment decisions. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJun 5

  eXoZymes uses AI engineered enzymes to make natural molecules outside the living cell. Chris Marlett, Chairman of the Board of eXoZymes (Nasdaq: $EXOZ ), used a May 2026 investor presentation to lay out the company’s cell free biomanufacturing platform. The platform takes the enzymes that build complex natural molecules and runs them outside the living cell, which the company says yields high purity at commercial scale and reaches molecules that are hard to extract or synthesize otherwise. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Here is how Marlett described what the platform can now do: “...we are now proving that we can actually make these and scale them, which is a first, which was sort of the dream of synthetic biology but was never really delivered upon. And we’re demonstrating that we can manufacture them at scale. So many of these people are using synbio and making human gram quantities and we’re now demonstrating that we can deliver them in ton quantities. And the big benefit of what we’re doing is it’s super pure.” The presentation also covered: • A platform that takes enzymes out of the cell and evolves them to run at industrial scale, building on more than a decade of cell free research • A focus on natural molecules that are difficult to extract or synthesize through traditional methods • Technology transfer to a third party contract manufacturer to support scale up from lab to commercial volumes • The ability to engineer more potent and more bioavailable analogs of the molecules it produces Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology that uses AI engineered enzymes to convert feedstocks into high value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG

• 
  David Shapiro@B2iDigitalJun 1

  eXoZymes (Nasdaq: $EXOZ ) details how its cell-free platform produces the enzyme function data that powers AI-driven biomanufacturing. eXoZymes Inc. (Nasdaq: EXOZ) shared a video in which Tyler Korman, PhD, Co-founder and VP of Research, explains why AI is well suited to enzyme engineering and why the company’s ability to generate unique enzyme function data may set its cell-free platform apart. eXoZymes is a B2i Digital Featured Company. See the company’s profile at b2idigital.com/exozymes-1. In the video, Korman explains that AI is fundamentally a question of data. He compares the 20 amino acids that build proteins to the letters of an alphabet, where the same building blocks can be arranged into millions of proteins and enzymes, each with a different function. The obstacle, he notes, has been the readout: AI can predict what a protein’s letters and structure might look like, but the function itself often remains unknown. eXoZymes is focused on closing that gap by measuring enzyme function directly, generating the data its models learn from. By making targeted changes to amino acids and observing the effect on function, the team can design, build, and test enzymes without first passing sequences through an organism or conducting sequencing, which helps shorten the work of generating and screening enzyme libraries. Looking further out, Korman points to linking enzyme steps into cascades of reactions, coupling biological pathways to move from low-cost inputs to nutraceuticals, pharmaceuticals, and specialty chemicals more efficiently. As Korman put it, the ability to generate this function data is “where some of our secret power lies,” helping eXoZymes refine its models and continue learning with large language models. Watch the video: https://exozymes.com/blog/exoz-ai-part1 Learn more at https://exozymes.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG

• 
  SuperGreenToday@SuperGreenTodayMay 27

  $DNLI Share Price: $19.84 Contract Selected: Dec 18, 2026 $20 Calls Buy Zone: $3.31 – $4.09 Target Zone: $5.72 – $6.99 Potential Upside: 63% ROI Time to Expiration: 204 Days | Updates via https://fxcapta.com/stockinfo/

  View on StockTwits ↗
• 
  John H2O@onlyGreenPlzMay 22

  $DNLI still upside. Lots of potential in their pipeline. Like many neurodegenerative diseases, early intervention matters. Now awaiting BEACON readout.

  View on StockTwits ↗
• 
  Bull Donald@BullDonaldMay 22

  $DNLI Position reduced Aggressively and as the Thesis changed from LUMA success to Market readjustment based on Pipeline. Reduce Portfolio exposure to less then 6% from ~60%. its a Miss, i would be Multi Banger if LUMA data show even 20% effecasy. But the stock held wll and did not crass. shows how Institution are defending the 18 price level.

  View on StockTwits ↗
• 
  Donald Osullivan@FibonacciTrader_May 22

  New trade update — full risk-off rotation just triggered in the book. Exited $DNLI completely after the LUMA trial failure (primary + all secondary endpoints missed, Parkinson’s program discontinued). Thesis was binary, and once that broke, position logic broke with it. No hesitation — capital preserved. Proceeds moved into $SGOV (short-term Treasuries). No replacement trade for now. Not forcing exposure into a weak opportunity set just for deployment’s sake. Cash = optionality, especially with multiple macro binaries ahead (Fed June decision, oil volatility, event-driven risk). Discipline > conviction when the thesis changes. Holding becomes ego, not edge. Rest of the book remains unchanged — stepping back, reassessing, and waiting for a cleaner setup before redeploying risk

  View on StockTwits ↗
• 
  Bull Donald@BullDonaldMay 22

  $DNLI Contrary to the news , Accumulation is happening. the binary event risk was priced in. that explained the Fall after Approval.

  View on StockTwits ↗
• 
  Chance@MaggistockBullishMay 22

  $DNLI Holding up really well!!

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.